Nineteen Twenty-One
Fredrik Debong
Fredrik Debong has spent 40 years living with type 1 diabetes - first as a patient, then as the founder who revolutionized its management with mySugr (acquired by Roche), and now as the visionary behind Nineteen Twenty-One. This is more than investing; it's a personal mission to transform a $1.2 trillion market that's still failing millions. While most funds chase broad healthtech trends, 1921 VC backs scientists and founders creating breakthrough solutions for diabetes and related health issues.
Visit Website
About Nineteen Twenty-One.
The beauty of 1921 VC lies in its singular focus and founder-GP symbiosis. Fredrik's journey from patient to entrepreneur to investor has created a unique vantage point - he sees opportunities where others see obstacles and speaks the language of clinicians, regulators, and engineers with equal fluency. After building mySugr into a category leader and achieving one of Europe's landmark digital health exits, he refined his investment thesis through 26 angel investments that delivered a 4.6x MOIC in diabetes-focused companies.
Nineteen Twenty-One represents the crystallization of this experience into a disciplined investment vehicle. The fund targets pre-seed to Series A companies developing everything from AI-powered diagnostic tools to next-generation therapies. What truly differentiates 1921 VC is its embedded advantage. Fredrik has assembled what might be the world's most concentrated network of diabetes expertise - Roche alumni, UCSF researchers, FDA advisors, and patient advocates who become active participants in portfolio companies. When a startup needs to design a clinical trial, they access scientists who've run hundreds. When facing regulatory hurdles, they get counsel from those who've shaped policy. This isn't just capital - it's an entire ecosystem distilled into competitive advantage.
Nineteen Twenty-One
Fund size:
EUR 10 Million
Nineteen Twenty-One represents a rare alignment of expertise and opportunity. With diabetes care at an inflection point - where AI, biotechnology, and patient-centered design are converging - the fund is positioned to back the next generation of category-defining companies. Fredrik's unique perspective as a patient, founder, and investor creates a distinct advantage in identifying and supporting teams that can translate innovation into real-world impact.
